Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Immepip. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Immepip SCHEMBL6347746 | 0.98 | HRH3 (0.46) | HRH3HRH4GBA1SLC6A4JAK2 | |
| Immepip SCHEMBL6605805 | 0.96 | HRH3 (0.45) | HRH3HRH4GBA1SLC6A4JAK2 | |
| SCHEMBL8515210 | 0.88 | HRH3 (0.49) | HRH3HRH4GBA1SLC6A4 | |
| SCHEMBL28079718 | 0.87 | — | — | |
| SCHEMBL14307810 | 0.83 | HRH4 (0.42) | HRH3HRH4 | |
| SCHEMBL6449281 | 0.81 | HRH4 (0.44) | HRH3HRH4 | |
| SCHEMBL6353897 | 0.81 | HRH3 (0.49) | HRH3HRH4GBA1SLC6A4 | |
| Bromide SCHEMBL15130221 | 0.80 | HRH3 (0.50) | HRH3HRH4SLC6A4 | |
| SCHEMBL14143044 | 0.79 | HRH3 (0.35) | HRH3HRH4 | |
| SCHEMBL14140514 | 0.79 | HRH3 (0.32) | HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-6951944-B2 | Production of imidazole derivatives and novel intermediates of the derivatives | AZWELL INC. (JP) | 2005-10-04 | — | — | US | disclosed |
| US-20050043277-A1 | Production of imidazole derivatives and novel intermediates of the derivatives | AZWELL INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1477487-A1 | IMPROVEMENT IN THE PRODUCTION OF IMIDAZOLE DERIVATIVES AND NOVEL INTERMEDIATES OF THE DERIVATIVES | Azwell Inc. (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | SLC6A4 4534/4885HRH3 681/4885HRH4 94/4885 |
| US-20050043277-A1 | Production of imidazole derivatives and novel intermediates of the derivatives | HRH3, HRH4, HRH2 | SLC6A4 2892/4885HRH3 1/4885HRH4 2/4885 |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | SLC6A4 4534/4885HRH3 681/4885HRH4 94/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | SLC6A4 4526/4885HRH3 774/4885HRH4 103/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | SLC6A4 2236/4885HRH3 548/4885HRH4 25/4885 |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | SLC6A4 4566/4885HRH3 601/4885HRH4 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.